AGENT Paclitaxel-Coated Balloon Catheter
BOSTON SCIENTIFIC CORPORATION · Decision date Feb 11, 2026
What did the FDA approve?
FDA records P230035/S006 as a supplement to PMA P230035, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Feb 11, 2026.
FDA approval order statement
a manufacturing site change to include Boston Scientific Ltd., located at Ballybrit Business Park, Galway, Ireland, for drug coating manufacturing, packaging and labeling for the Agent Monorail Paclitaxel Coated Balloon Catheter
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 11, 2026
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230035/S006
- Regulatory pathway
- PMA supplement
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- OOB
- Decision code
- APPR
- Decision date
- Feb 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-eluting percutaneous transluminal coronary angioplasty catheter.
- Applicant
- Boston Scientific Corporation
- Product code
- OOB
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P230035/S006 received
Application receipt date recorded by FDA.
P230035/S007 · Related supplement
AGENT Paclitaxel-Coated Balloon Catheter
P230035/S006 · FDA decision
Normal 180 Day Track No User Fee
P230035/S009 · Related supplement
AGENT Paclitaxel-Coated Balloon Catheter
P230035/S010 · Related supplement
AGENT Paclitaxel-Coated Balloon Catheter
Timeline entries are records held by MedtechLedger for P230035. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230035
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AGENT Paclitaxel-Coated Balloon CatheterP230035/S007 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Oct 24, 2025 | FDA |
AGENT Paclitaxel-Coated Balloon CatheterP230035/S009 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Jul 30, 2026 | FDA |
AGENT Paclitaxel-Coated Balloon CatheterP230035/S010 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 28, 2026 | FDA |
Explore the linked device profile
Other records with product code OOB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SELUTION SLR 014 PTCA Drug-Eluting BalloonP250041/S001 | MedAlliance, LLC | PMA supplement | Nov 6, 2026 | FDA |
| MedAlliance, LLC | PMA approval | Sep 18, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- One Scimed Pl., Maple Grove, MN, 55311
Sources and methodology
- Original FDA record: P230035/S006
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

